Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Cosmos Health entered a five-year agreement with Libytec to commercialize its generic diabetes drug DIABIT-IS X in the Greek market. The product, a sitagliptin phosphate tablet, is expected to be accessible through the national health insurance system, broadening its patient reach.
Key figures
- Term years
- 5
- Dosage strengths
- 50 mg, 100 mg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.